



(51) International Patent Classification:

C12N 15/44 (2006.01) *C12N 15/82* (2006.01)
A01H 5/00 (2018.01) *C12N 5/10* (2006.01)
A61K 39/145 (2006.01) *C12N 7/00* (2006.01)
C07K 14/11 (2006.01) *C12N 7/01* (2006.01)
C07K 16/10 (2006.01) *C12P 21/00* (2006.01)

(21) International Application Number:

PCT/CA2019/050891

(22) International Filing Date:

27 June 2019 (27.06.2019)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/690,780 27 June 2018 (27.06.2018) US

(71) Applicant: **MEDICAGO INC.** [CA/CA]; 600 - 1020
 Route de l'Eglise, QUEBEC, Québec G1V 3V9 (CA).

(72) Inventors: **LAVOIE, Pierre-Olivier**; 621 Franklin, QUE-
 BEC, Québec G1N 2L7 (CA). **LORIN, Aurélien**; 2624
 Rue du Père-Druillettes, QUEBEC, Québec G1V 1B1
 (CA). **DOUCET, Alain**; 245, rue Hamel, Saint-Gilles,

Québec G0S 2P0 (CA). **D'AOUST, Marc-André**; 3925
 Rue Louise-Fiset, QUEBEC, Québec G1X 4N4 (CA).
COUTURE, Manon; 4880, Lionel-Groulx app. 301, St-
 Augustin-de-Desmaures, Québec G3A 1Z5 (CA).


(74) Agent: **SECHLEY, Konrad** et al.; c/o Gowling WLG
 (Canada) LLP, 2300 - 550 Burrard Street, Vancouver,
 British Columbia V6C 2B5 (CA).

(81) Designated States (unless otherwise indicated, for every
 kind of national protection available): AE, AG, AL, AM,
 AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
 CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
 DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
 HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,
 KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
 MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
 OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
 SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
 TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
 kind of regional protection available): ARIPO (BW, GH,
 GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
 UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,

(54) Title: INFLUENZA VIRUS HEMAGGLUTININ MUTANTS

Figure 3B



(57) Abstract: The present invention relates to the production of modified influenza viral proteins in plants. More specifically, the present invention relates to producing and increasing influenza virus-like particle (VLP) production in plants, wherein the VLPs comprise the modified influenza viral proteins, such as modified influenza hemagglutinin (HA). The HA protein may comprising an amino acid sequence comprising at least one substitution when compared to a corresponding wildtype amino acid sequence. Further provided are nucleic acid encoding the modified HA protein. Furthermore methods of producing an influenza virus like particle (VLP) and methods of increasing yield of production of an influenza virus like particle (VLP) in a plant, portion of a plant, or a plant cell, are also provided.

[Continued on next page]

TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*
- *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*